학술논문
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
Document Type
Article
Author
Source
In Annals of Oncology April 2019 30(4):644-651
Subject
Language
ISSN
0923-7534